Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/54649 |
Resumo: | Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| id |
CRUZ_07a7e6c737bf5314884905df0cbf5ad2 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/54649 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Bravo, LuluSmolenov, IgorHan, Htay HtayLi, PingHosain, RomanaRockhold, FrankClemens, Sue Ann CostaRoa Jr, CamiloBorja-Tabora, CharissaQuinsaat, AntoinetteLopez, PioLópez-Medina, EduardoBrochado, LeonardoHernández, Eder A.Reynales, HumbertoMedina, TatianaVelasquez, HectorToloza, Leonardo BautistaRodriguez, Edith JohanaSalazar, Dora Ines Molina deRodríguez, Camilo A.Sprinz, EduardoCerbino-Neto, JoséLuz, Kleber GiovanniSchwarzbold, Alexandre VargasPaiva, Maria SanaliCarlos, JosefinaMontellano, May Emmeline B.Los Reyes, Mari Rose A. deYu, Charles Y.Alberto, Edison R.Panaligan, Mario M.Salvani-Bautista, MilagrosBuntinx, ErikHites, MayaMartinot, Jean-BenoitBhorat, Qasim E.Badat, AyshaBaccarini, CarmenHu, BrandaJurgens, JacoEngelbrecht, JanAmbrosino, DonnaRichmond, PeterSiber, GeorgeLiang, JoshuaClemens, Ralf2022-08-16T11:20:00Z2022-08-16T11:20:00Z2022BRAVO, Lulu et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet, v. 399, p. 461-472, 20221474-547Xhttps://www.arca.fiocruz.br/handle/icict/5464910.1016/S0140-6736(22)00055-1Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.University of the Philippines Manila. Ermita, Manila, Philippines.Clover Biopharmaceuticals. Cambridge, MA, USA.Clover Biopharmaceuticals. Cambridge, MA, USA.Clover Biopharmaceuticals. Cambridge, MA, USA.Clover Biopharmaceuticals. Cambridge, MA, USA.Duke University Medical Center. Duke University Clinical Research Institute. Durham, NC, USA.University of Oxford. Oxford Vaccine Group. Oxford, UK.Manila Doctors Hospital. Manila, Philippines.Asian Hospital and Medical Center. Alabang, Muntinlupa, Philippines.Global Research in Infectious Diseases. Singapore.Universidad Del Valle Clínica Imbanaco. Centro de Estudios en Infectología Pediátrica. Cali, Colombia.Universidad Del Valle Clínica Imbanaco. Centro de Estudios en Infectología Pediátrica. Cali, Colombia.Clinica De La Costa. Barranquilla, Atlantico, Colombia.Hospital Universidad del Norte. Barranquilla, Colombia.Center of Attention in Medical Research. Bogotá, Colombia.Center of Attention in Medical Research. Bogotá, Colombia.Center of Attention in Medical Research. Bogotá, Colombia.Center of Attention in Medical Research. Bogotá, Colombia.Center of Attention in Medical Research. Bogotá, Colombia.Faculty of Health Sciences at the University of Caldas. Manizales, Colombia.Policlínico Social del Norte. Bogotá, Colombia.Federal University of Rio Grande do Sul. Hospital de Clinicas de Porto Alegre. Porto Alegre, RS, Brazil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.Federal University of Rio Grande do Norte. Natal, RN,Brazil.Universidade Federal de Santa Maria. Infectious Diseases Division. Rio Grande do Sul, Brazil.Atena Institute of Clinical Research. Natal, RN, Brazil.University of the East Ramon Magsaysay Memorial Medical Center. Quezon City, Philippines.Far Eastern University Hospital - Nicanor Reyes Medical Foundation. Quezon City, Philippines.Las Pinas Doctors Hospital. Las Pinas City, Philippines.De La Salle Medical and Health Sciences Institute. Cavite City, Philippines.Tropical Disease Foundation. Cavite City, Philippines.St Luke's Medical Center. Infection Control Service. Taguig, Philippines.University of the East Ramon Magsaysay Memorial Medical Center. Quezon City, Philippines.Anima Research Center. Alken, Belgium.Clinic of Infectious Diseases. CUB-Hôpital Erasme. Bruxelles, Belgium.CHU Universite Catholique de Louvain Namur Site Sainte-Elisabeth. Pulmonology Department. Namur, Belgium.Soweto Clinical Trials Centre. Johannesburg, South Africa.Wits Clinical Research. Soweto, Johannesburg, South Africa.Clover Biopharmaceuticals. Cambridge, MA, USA.Clover Biopharmaceuticals. Cambridge, MA, USA.DJW Research. Krugersdorp, Gauteng, South Africa.Dr JM Engelbrecht Trial Site. Vergelegen Mediclinic. Western Cape, South Africa.Independent Advisor. Stuart, FL, USA.University of Western Australia. Division of Paediatrics. Wesfarmers Centre of Vaccines. Perth, WA, Australia / Telethon Kids Institute. Infectious Diseases. Perth, WA, Australia / Perth. Children's Hospital. Perth, WA, Australia.Independent Advisor. New York, NY, USA.Clover Biopharmaceuticals. Chengdu, China.Global Research in Infectious Diseases. Rio de Janeiro, RJ, Brazil.engEfficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trialinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleCOVID-19Vaccine SCB-2019SARS-CoV-2info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83099https://www.arca.fiocruz.br/bitstream/icict/54649/1/license.txt586c046dcfeef936e32f0323bb9a47c0MD51ORIGINALEfficacy_Jose_Cerbino_etal_INI_2022.pdfEfficacy_Jose_Cerbino_etal_INI_2022.pdfapplication/pdf457359https://www.arca.fiocruz.br/bitstream/icict/54649/2/Efficacy_Jose_Cerbino_etal_INI_2022.pdff8becb1ede66dccf6cccb047b9da9bdeMD52icict/546492023-02-15 22:43:20.0oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-02-16T01:43:20Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial |
| title |
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial |
| spellingShingle |
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial Bravo, Lulu COVID-19 Vaccine SCB-2019 SARS-CoV-2 |
| title_short |
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial |
| title_full |
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial |
| title_fullStr |
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial |
| title_full_unstemmed |
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial |
| title_sort |
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial |
| author |
Bravo, Lulu |
| author_facet |
Bravo, Lulu Smolenov, Igor Han, Htay Htay Li, Ping Hosain, Romana Rockhold, Frank Clemens, Sue Ann Costa Roa Jr, Camilo Borja-Tabora, Charissa Quinsaat, Antoinette Lopez, Pio López-Medina, Eduardo Brochado, Leonardo Hernández, Eder A. Reynales, Humberto Medina, Tatiana Velasquez, Hector Toloza, Leonardo Bautista Rodriguez, Edith Johana Salazar, Dora Ines Molina de Rodríguez, Camilo A. Sprinz, Eduardo Cerbino-Neto, José Luz, Kleber Giovanni Schwarzbold, Alexandre Vargas Paiva, Maria Sanali Carlos, Josefina Montellano, May Emmeline B. Los Reyes, Mari Rose A. de Yu, Charles Y. Alberto, Edison R. Panaligan, Mario M. Salvani-Bautista, Milagros Buntinx, Erik Hites, Maya Martinot, Jean-Benoit Bhorat, Qasim E. Badat, Aysha Baccarini, Carmen Hu, Branda Jurgens, Jaco Engelbrecht, Jan Ambrosino, Donna Richmond, Peter Siber, George Liang, Joshua Clemens, Ralf |
| author_role |
author |
| author2 |
Smolenov, Igor Han, Htay Htay Li, Ping Hosain, Romana Rockhold, Frank Clemens, Sue Ann Costa Roa Jr, Camilo Borja-Tabora, Charissa Quinsaat, Antoinette Lopez, Pio López-Medina, Eduardo Brochado, Leonardo Hernández, Eder A. Reynales, Humberto Medina, Tatiana Velasquez, Hector Toloza, Leonardo Bautista Rodriguez, Edith Johana Salazar, Dora Ines Molina de Rodríguez, Camilo A. Sprinz, Eduardo Cerbino-Neto, José Luz, Kleber Giovanni Schwarzbold, Alexandre Vargas Paiva, Maria Sanali Carlos, Josefina Montellano, May Emmeline B. Los Reyes, Mari Rose A. de Yu, Charles Y. Alberto, Edison R. Panaligan, Mario M. Salvani-Bautista, Milagros Buntinx, Erik Hites, Maya Martinot, Jean-Benoit Bhorat, Qasim E. Badat, Aysha Baccarini, Carmen Hu, Branda Jurgens, Jaco Engelbrecht, Jan Ambrosino, Donna Richmond, Peter Siber, George Liang, Joshua Clemens, Ralf |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Bravo, Lulu Smolenov, Igor Han, Htay Htay Li, Ping Hosain, Romana Rockhold, Frank Clemens, Sue Ann Costa Roa Jr, Camilo Borja-Tabora, Charissa Quinsaat, Antoinette Lopez, Pio López-Medina, Eduardo Brochado, Leonardo Hernández, Eder A. Reynales, Humberto Medina, Tatiana Velasquez, Hector Toloza, Leonardo Bautista Rodriguez, Edith Johana Salazar, Dora Ines Molina de Rodríguez, Camilo A. Sprinz, Eduardo Cerbino-Neto, José Luz, Kleber Giovanni Schwarzbold, Alexandre Vargas Paiva, Maria Sanali Carlos, Josefina Montellano, May Emmeline B. Los Reyes, Mari Rose A. de Yu, Charles Y. Alberto, Edison R. Panaligan, Mario M. Salvani-Bautista, Milagros Buntinx, Erik Hites, Maya Martinot, Jean-Benoit Bhorat, Qasim E. Badat, Aysha Baccarini, Carmen Hu, Branda Jurgens, Jaco Engelbrecht, Jan Ambrosino, Donna Richmond, Peter Siber, George Liang, Joshua Clemens, Ralf |
| dc.subject.en.pt_BR.fl_str_mv |
COVID-19 Vaccine SCB-2019 SARS-CoV-2 |
| topic |
COVID-19 Vaccine SCB-2019 SARS-CoV-2 |
| description |
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| publishDate |
2022 |
| dc.date.accessioned.fl_str_mv |
2022-08-16T11:20:00Z |
| dc.date.available.fl_str_mv |
2022-08-16T11:20:00Z |
| dc.date.issued.fl_str_mv |
2022 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
BRAVO, Lulu et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet, v. 399, p. 461-472, 2022 |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/54649 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1474-547X |
| dc.identifier.doi.none.fl_str_mv |
10.1016/S0140-6736(22)00055-1 |
| identifier_str_mv |
BRAVO, Lulu et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet, v. 399, p. 461-472, 2022 1474-547X 10.1016/S0140-6736(22)00055-1 |
| url |
https://www.arca.fiocruz.br/handle/icict/54649 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/54649/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/54649/2/Efficacy_Jose_Cerbino_etal_INI_2022.pdf |
| bitstream.checksum.fl_str_mv |
586c046dcfeef936e32f0323bb9a47c0 f8becb1ede66dccf6cccb047b9da9bde |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1798325053876600832 |